# Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C

> **NCT01649245** · PHASE4 · UNKNOWN · sponsor: **MinaPharm Pharmaceuticals** · enrollment: 5000 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Reiferon retard

## Key facts

- **NCT ID:** NCT01649245
- **Lead sponsor:** MinaPharm Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649245, "Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01649245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*